BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,140 filers reported holding BAXTER INTL INC in Q4 2021. The put-call ratio across all filers is 1.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $221,000 | -19.6% | 2,844 | -11.2% | 0.01% | -18.2% |
Q4 2021 | $275,000 | +3.8% | 3,204 | -2.9% | 0.01% | -8.3% |
Q3 2021 | $265,000 | -7.3% | 3,298 | -7.0% | 0.01% | -7.7% |
Q2 2021 | $286,000 | +8.3% | 3,547 | +13.4% | 0.01% | -7.1% |
Q1 2021 | $264,000 | +30.7% | 3,128 | +24.3% | 0.01% | +40.0% |
Q4 2020 | $202,000 | -3.3% | 2,517 | -3.0% | 0.01% | -9.1% |
Q3 2020 | $209,000 | -10.3% | 2,595 | -4.2% | 0.01% | -15.4% |
Q2 2020 | $233,000 | +5.9% | 2,709 | 0.0% | 0.01% | -13.3% |
Q1 2020 | $220,000 | -14.4% | 2,709 | -11.8% | 0.02% | 0.0% |
Q4 2019 | $257,000 | -15.5% | 3,072 | -11.5% | 0.02% | -21.1% |
Q3 2019 | $304,000 | +0.3% | 3,472 | -6.5% | 0.02% | -5.0% |
Q2 2019 | $303,000 | -1.6% | 3,712 | -2.1% | 0.02% | -4.8% |
Q1 2019 | $308,000 | +27.3% | 3,792 | +3.0% | 0.02% | +16.7% |
Q4 2018 | $242,000 | +0.4% | 3,682 | +17.9% | 0.02% | -5.3% |
Q3 2018 | $241,000 | +3.4% | 3,122 | -1.0% | 0.02% | -9.5% |
Q2 2018 | $233,000 | +3.1% | 3,154 | -9.4% | 0.02% | +10.5% |
Q1 2018 | $226,000 | +1.3% | 3,482 | +0.9% | 0.02% | -5.0% |
Q4 2017 | $223,000 | -6.3% | 3,450 | -8.9% | 0.02% | +5.3% |
Q3 2017 | $238,000 | -11.2% | 3,789 | -14.5% | 0.02% | -17.4% |
Q2 2017 | $268,000 | +13.6% | 4,429 | -2.6% | 0.02% | +9.5% |
Q1 2017 | $236,000 | +14.0% | 4,547 | -2.7% | 0.02% | -4.5% |
Q4 2016 | $207,000 | – | 4,675 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |